Pfizer and Bausch & Lomb announced a co-promotion deal for both companies’ prescription ophthalmic pharmaceuticals in the US. The five year agreement includes Pfizer’s Xalatan, and Bausch & Lomb’s Alrex, Lotemax, Zylet, and the company’s investigational anti-infective eye drop, besifloxacin ophthalmic suspension (0.6%), which is currently under FDA review.
Pfizer has entered into agreements with Aurobindo Pharma, an India-based pharmaceutical company, to commercialize generic medications in the US and Europe. The move progresses the company’s established products business unit, which is focused on the commercialization of products where market exclusivity has been lost.
